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Objective: To compare DMARD use in patients with and without FM over time, including
overtreatment and undertreatment rates in both groups.
Methods: A prospective cohort study with patients attending an RA outpatient clinic was con-
ducted. Participants were consecutively recruited between March 2006 and June 2007 and
were followed through December 2013. Data on DMARD use (prevalences, doses and esca-
lation rates), DAS28, HAQ and radiographic progression were compared among RA patients
with FM and without FM. Mistreatment clinical scenarios were allegedly identified and
compared between groups.
Results: 256 RA patients (32 with FM) were followed for 6.2 ± 2.0 (mean ± SD) years comprising
2986 visits. At baseline, RA duration was 11.1 ± 7.4 years. DAS28 and HAQ were greater in RA
with FM group, and were closer to RA without FM group towards the end. RA patients with FM
used higher doses of tricyclic antidepressants, leflunomide and prednisone, and lower doses
of  methotrexate. When compared to RA patients without FM,  participants with RA and FM
used  more often tricyclic antidepressants, leflunomide, prednisone, continuous analgesicsand  less often methotrexate. Groups presented similar 7-year biologic-free survival, and
radiographic progression-free survival in Cox regression. RA patients with FM had greater
proportions of visits in mistreatment scenarios when compared to RA patients without FM
(28.4 vs. 19.8%, p < 0.001).∗ Corresponding author.
E-mail: rafaelchakr@gmail.com (R.M. Chakr).
ttp://dx.doi.org/10.1016/j.rbre.2017.01.004
255-5021/© 2017 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
icenses/by-nc-nd/4.0/).
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Conclusions: RA patients with FM used more leflunomide and prednisone, and RA mistreat-
ment was more frequent in FM patients. Certainly, RA patients with FM will benefit from a
personalized T2T strategy, including ultrasound (when suitable) and proper FM treatment.
©  2017 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
As  decisões  de  tratamento  com  DMARD  na  artrite  reumatoide  parecem
ser  influenciadas  pela  fibromialgia
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r  e  s  u  m  o
Objetivo: Comparar o uso de fármacos antirreumáticos modificadores da doenc¸a (DMARD)
em  pacientes com e sem fibromialgia (FM) ao longo do tempo, incluindo as taxas de trata-
mento excessivo e subtratamento em ambos os grupos.
Métodos: Estudo de coorte prospectiva com pacientes atendidos em um ambulatório de
artrite reumatoide (AR). Os participantes foram recrutados consecutivamente entre marc¸o
de  2006 e junho de 2007 e foram seguidos até dezembro de 2013. Compararam-se os dados de
uso  de DMARD (prevalências, doses e taxas de escalonamento), 28-Joint Disease Activity Score
(DAS28), Health Assessment Questionnaire (HAQ) e progressão radiográfica entre pacientes com
e  sem FM. Os cenários clínicos de tratamento supostamente incorreto foram identificados
e  comparados entre os grupos.
Resultados: Seguiram-se 256 pacientes com AR (32 com FM) por 6,2 ± 2,0 (média ± DP) anos,
período que abrangeu 2.986 consultas. No início do estudo, a durac¸ão da AR era de 11,1 ± 7,4
anos. O DAS28 e o HAQ foram maiores no grupo AR com FM e estavam mais próximos do
grupo AR sem FM no fim do estudo. Os pacientes com AR com FM usaram doses mais altas
de  antidepressivos tricíclicos, leflunomida e prednisona e doses mais baixas de metotrex-
ato. Quando comparados com os pacientes com AR sem FM, os participantes com AR e FM
usaram mais frequentemente antidepressivos tricíclicos, leflunomida, prednisona e anal-
gésicos contínuos e menos frequentemente metotrexato. Os grupos apresentaram sobrevida
em  sete anos sem agentes biológicos e livres de progressão radiográfica semelhantes na
regressão Cox. Os pacientes com AR com FM apresentaram uma maior proporc¸ão de con-
sultas em cenários de tratamento supostamente incorreto quando comparados com os
pacientes com AR sem FM (28,4 vs. 19,8%, p < 0,001).
Conclusões: Os pacientes com AR e FM usaram mais leflunomida e prednisona e o tratamento
supostamente incorreto na AR foi mais frequente em pacientes com FM. Os pacientes com
AR  com FM certamente se beneficiarão de uma estratégia personalizada de tratamento por
metas (T2T), incluindo ultrassonografia (quando apropriado) e controle da FM.
©  2017 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma licenc¸a CCIntroduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease
characterized by chronic destructive polyarthritis that may
cause severe functional impairment and death.1 To stop joint
destruction and prevent worse outcomes clinicians should
use disease-modifying antirheumatic drugs (DMARD) in a
treat-to-target (T2T) strategy, where lower disease activity is
pursued.1–3 Disease activity level can be clinically estimated
by 28-joint disease activity score (DAS28), a score that includes
objective (number of swollen joints and erythrocyte sedi-
mentation rate) and subjective parameters (number of tender
joints and patient’s global health evaluation using a visual
4,5analogue scale).
Fibromyalgia (FM) is a chronic painful condition affect-
ing up to 20% of RA patients. FM may falsely increase RA
activity by augmenting the subjective components of DAS28BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
and, therefore, bias treatment decision. Both overtreatment
(DMARD escalation when a higher DAS28 is due to FM)  and
undertreatment (no DMARD escalation when a higher DAS28
is due to RA) are possible.6–10
The primary goal of this study is to compare DMARD use
in patients with and without FM over time. Also, we  intend
to compare overtreatment and undertreatment rates in both
groups.
Patients  and  methods
A prospective cohort study was conducted with patients
attending the RA outpatient clinic at Hospital de Clínicas de
Porto Alegre since biologic DMARD became available in the
institution. Participants were consecutively recruited between
March 2006 and June 2007 and they were followed through
December 2013. To be included patients had to fulfil 1987
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with and without FM were performed using Student’s andr e v b r a s r e u m a t o l
merican College of Rheumatology (ACR) classification crite-
ia for RA.11 Every participant was also assessed at baseline
or the diagnosis of FM according to 1990 ACR classifica-
ion criteria.12 There were two unmatched groups under
bservation: RA patients with FM and RA patients with-
ut FM.  Exclusion criteria were concomitant systemic lupus
rythematosus, systemic sclerosis, idiopathic inflammatory
yopathies, spondyloarthropathies, hepatitis B or C virus, or
uman immunodeficiency virus infection at baseline or dur-
ng follow-up. Participants were also excluded if they did not
ave FM at baseline but developed diffuse chronic pain after-
ards.
Data of each visit were collected in standardized research
orms. DAS28 (ranges from 0.0 through 9.4; greater values
epresent higher disease activity) and health assessment
uestionnaire (HAQ; greater values represent worse functional
tatus) calculation and FM diagnosis were made by differ-
nt blinded examiners.13,14 Charlson comorbidity index (CCI;
anges from 0 through 35; greater values represent higher
omorbidity) was also calculated at baseline.15
Hospital de Clínicas de Porto Alegre is a public tertiary
nstitution where patients have access to all DMARD as
art of a national Government-funded programme. Also,
nalgesics, nonsteroidal anti-inflammatory drugs (NSAID),
teroids, amitriptyline, fluoxetine and cyclobenzaprine are
rovided by the Government.
In the RA clinic, patients are treated according to a step-up
2T approach where DMARD are escalated up to remis-
ion or low disease activity.16 For the purpose of this study,
MARD escalation was defined as any dose increment or
rug switch to achieve treatment target, and treatment fail-
re was defined as consistently moderate/high disease activity
fter three months of the highest tolerated dose of a syn-
hetic DMARD or six months of a biologic DMARD. According
o T2T, methotrexate was the first prescribed DMARD and
tarted just after the diagnosis. If methotrexate monotherapy
ailed, a second line synthetic DMARD therapy was started.
his second synthetic DMARD step consisted of leflunomide
onotherapy, association of methotrexate and leflunomide
r association of methotrexate, sulfasalazine and hydrox-
lchloroquine (or chloroquine). If the second DMARD scheme
ailed, a biologic DMARD, preferably an anti-tumour necrosis
actor agent (anti-TNF), was started in association with a syn-
hetic DMARD, preferably methotrexate. Treatment failure to
he first biologic DMARD was an indication for biologic switch-
ng. Another anti-TNF, abatacept, rituximab and tocilizumab
ere the alternatives. The option for the next biologic took
nto account patients’ clinical aspects and preferences in light
f the existing evidence. Adalimumab, etanercept, infliximab
nd rituximab were available for use in the study centre since
ts onset in 2006. Abatacept and tocilizumab became available
n 2010, and certolizumab and golimumab, in 2012. Steroids
ould be used anytime at the lowest dose to control synovi-
is. Nonsteroidal anti-inflammatory drugs (NSAID) were used
or short periods of time to control worsening inflamma-
ory symptoms. Analgesics NSAID (acetaminophen, dipyrone,
ramadol, codeine) were used on demand for pain control.
MARD withdrawal was recommended in case of sustained
emission without radiographic progression and consisted
f gradual dose reduction or interval spacing over months. 7;5 7(5):403–411 405
Biologic DMARD should be withdrawn before synthetic
DMARD.2
During the study, patients were routinely assessed for the
presence of widespread pain. FM treatment consisted of drug
therapy, exercise and psychotherapy. Drug therapy included
on-demand analgesics and continuous amitriptyline, fluox-
etine, cyclobenzaprine, pregabalin or duloxetine. Pregabalin
and duloxetine are available for FM treatment in Brazil since
2011.17 FM patients were encouraged to attend the multidis-
ciplinary Pain Treatment clinic.
Every three months, RA patients should perform blood and
urine tests for drug safety monitoring. Tests for disease activ-
ity assessment were performed every three to six months.
Radiographic monitoring of RA damage was performed once
a year. Experienced musculoskeletal radiologists not aware of
RA activity level or FM diagnosis read the X-rays and radio-
graphic progression was defined in the presence of worsening
or appearance of joint space narrowing or typical joint ero-
sions in the hands or feet. Previous damage was visually
considered worse, as no measuring was performed. Absence
of radiographic progression was defined as no worsening or
appearance of joint space narrowing or typical hands and feet
erosions in two consecutive radiographs. After 2011, patients
could be referred for ultrasound examination of RA activ-
ity. The disease activity assessment by ultrasound comprised
seven joints (dominant wrist, second and third metacarpopha-
langeal, and second and fifth metatarsophalangeal joints)
plus any symptomatic joints (tender and swollen). Referral
for ultrasound examination and DMARD escalation decision
afterwards were based on free clinician’s judgement.
To verify the potential role of FM in inducing RA mis-
treatment, two clinical scenarios were analyzed. Scenario
A comprised visits with continuous moderate/high disease
activity despite DMARD escalation (treatment failure) with-
out radiographic progression. In other words, whenever
DMARD treatment was not escalated (DAS28 moderate/high)
and radiographic progression was noticed, undertreatment
was present. Scenario B comprised visits with persistent
moderate/high disease activity without DMARD escalation
but with radiographic progression identified. Therefore, in
the absence of radiographic progression despite persistently
moderate/high DAS28, DMARD escalation was considered
overtreatment. Allegedly, scenarios A and B respectively rep-
resent overtreatment and undertreatment.
Statistical analyses were executed in SPSS software (SPSS
Inc. Released 2009. PASW Statistics for Windows, Version 18.0.
Chicago: SPSS Inc.). Previously, a difference of 0.29 in propor-
tions of individuals with and without FM with moderate/high
RA activity (0.97 and 0.68, respectively) was reported.6 Our
cohort of 32 RA patients with FM and 224 without FM had a
power of 0.88 to detect such a difference with an alpha of 0.050.
Outcome measures were mainly reported as rates (per patient-
year) or frequencies (%) and measures of central tendency
were mean ± standard deviation (SD) and median (interquar-
tile range, IQR). Each variable distribution was tested for nor-
mality by Shapiro–Wilk’s test. Comparisons between groupsMann–Whitney’s tests for continuous variables and Pearson’s
chi-square test for categorical variables. To compare DAS28
and HAQ over time between groups, generalized estimating
 o l . 2406  r e v b r a s r e u m a t
equations were used. Biologic DMARD-free survival, and
radiographic progression-free survival were compared using
Kaplan–Meier curves and tested using Cox proportional haz-
ards models. Results of the Cox regressions were presented as
hazard ratios (HR) and 95% confidence interval (CI). A p value
of less than 0.050 was considered statistically significant.
This study was approved by the Research Ethics Commit-
tees of Hospital de Clínicas de Porto Alegre and Universidade
Federal do Rio Grande do Sul. All patients signed written
informed consent before entering the original cross-sectional
study in 2006 and 2007,6 and researchers signed a data utiliza-
tion form to comply with the Declaration of Helsinki.
Results
Initially, 270 patients were recruited, but 14 participants
were excluded due to diffuse pain or overlap syndrome
development. Totally, 256 patients were followed for 6.2 ± 2.0
(mean ± SD) years (Table 1). They were mostly middle-aged
(55.4 ± 12.6 years), caucasian (85.2%), married (50.4%), women
(84.4%) with ≤8 years of school attendance (75.4%). Data from
2986 visits were analyzed. All patients regularly performed
hands and feet radiographs throughout follow-up.
At baseline, FM was present in 12.5% of the participants
(n = 32), Sjögren’s syndrome in 4.7%, rheumatoid factor in
83.6% and joint erosions in 83.6%. Participants had RA for
11.1 ± 7.4 years and their CCI was 1.7 ± 1.0. Overall, DAS28 and
HAQ scores significantly decreased from 4.1 ± 1.9 to 3.5 ± 1.4
(p < 0.001) and from 1.8 ± 0.8 to 0.7 ± 0.7 (p < 0.001), respectively.Initially, RA patients with FM were slightly older, predom-
inantly female and had greater DAS28 and HAQ compared
to those without FM (Table 1). DAS28 and HAQ values were
superior in RA with FM over time (Fig. 1). At the end of the
Table 1 – Baseline patients characteristics.
R
Age; mean (±SD) 59.9
Female (%) 96.9
Years since RA diagnosis; mean (±SD) 11.0
Years since FM diagnosis; mean (±SD) 5.8
Charlson comorbidity index; mean (±SD) 1.8
DAS28; mean (±SD) 5.3
Swollen joints count; median (IQR) 3.9
Tender joints count; median (IQR) 10.0
Patient’s global health visual analogue scale; median (IQR) 56.5
ESR (mm/h); median (IQR) 28.5
HAQ; mean (±SD) 2.3
Caucasian (%) 93.8
Eight or less years of school (%) 78.2
Married (%) 37.5
Sjögren’s syndrome (%) 3.1
Rheumatoid factor positive (%) 81.3
Joint erosions present on X-ray (%) 74.2
RA, rheumatoid arthritis; FM, fibromyalgia; DAS28, 28-joint disease activity
questionnaire; SD, standard deviation; IQR, interquartile range.
a Student’s, Mann–Whitney’s or Pearson’s chi-square test was used accord
with statistical significance. 0 1 7;5 7(5):403–411
study, DAS28 and HAQ were superior in RA patients with
FM:  4.2 ± 1.3 vs. 3.3 ± 1.3, p = 0.001, and 1.3 ± 0.8 vs. 0.7 ± 0.7,
p < 0.001, respectively. However, FM patients exhibited a
greater decrease in DAS28 and HAQ values throughout the
study (Fig. 1). According to generalized estimating equations
analyses, between-group comparisons, intra-group (time-
based) comparisons and group-time interactions were all
statistically significant (p < 0.001). In other words, groups dif-
fered between each other, both of them changed over time and
they did so in different ways.
Considering treatment response, 37.5% and 39.7%
(p = 0.809) of RA patients with and without FM,  respec-
tively, had moderate/high disease activity at baseline and
went down to remission/low disease activity in the last visit.
In terms of remission rates, at baseline, 0.0% of patients
with FM and 24.6% of patients without FM were in remission
(p = 0.002), and, by the end of the study, remission rates were
18.8% and 32.1%, respectively (p = 0.124).
During follow up, amitriptyline was used by 24.2% of partic-
ipants at 25.0 (25.0, 50.0) mg/day [median (IQR)], methotrexate
by 89.5% at 20.0 (15.0, 20.0) mg/day, leflunomide by 50.8%
at 20.0 (20.0, 20.0) mg/day, prednisone by 79.3% at 7.5 (5.0,
10.0) mg/day and biologic DMARD by 21.9% of individuals.
RA patients with FM used higher doses of tricyclic antide-
pressants, leflunomide and prednisone, and lower doses of
methotrexate (Table 2). Doses of prednisone prescribed by the
physician in each visit were also higher among RA patients
with FM:  5.0 (0.0, 10.0) vs. 2.5 (0.0, 7.5), p < 0.001. More  RA
patients with FM used tricyclic antidepressants than those
without FM (Table 2). Cyclobenzaprine, fluoxetine, pregabalin,
duloxetine, sulfasalazine, chloroquine and hydroxychloro-
quine were used by fewer than 50.0% of participants each. No
patients used certolizumab or golimumab during the study.
When compared to RA patients without FM,  participants
A with FM RA  without FM p valuea
(n = 32) (n = 224)
 (±12.8) 54.7 (±12.5) 0.028
 82.6 0.037
 (±7.7) 11.1 (±7.3) 0.911
 (±3.9) – –
 (±1.0) 1.7 (±1.0) 0.388
 (±1.1) 3.9 (±1.5) <0.001
 (1.0–5.5) 2.4 (0.0–5.0) 0.122
 (5.0–17.0) 3.0 (0.0–8.0) <0.001
 (41.5–90.0) 31.5 (14.0–52.2) <0.001
 (15.5–49.0) 26.0 (14.0–41.2) 0.335
 (±0.5) 1.7 (±0.8) 0.001
 83.9 0.233
 75.1 0.947
 52.2 0.135
 4.9 0.655
 83.9 0.702
 85.7 0.101
 score; ESR, erythrocyte sedimentation rate; HAQ, health assessment
ing to nature and distribution of data; alpha = 0.050. In bold, p values
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ith RA and FM used more  often tricyclic antidepressants,
eflunomide, prednisone, continuous analgesics and less often
ethotrexate throughout the study (Table 3). No difference
as observed between groups regarding the prevalences of
iologic DMARD use and DMARD escalations (Table 3).
Overall, DMARD escalation rate was 1.0 (0.7, 1.5) DMARD
scalation/patient-year. In terms of biologics use, RA patients
ere on average under biologic DMARD in less than one visit
er year (0.9 ± 0.5 visit under biologic DMARD/patient-year).
MARD escalation and biologics use did not differ between
roups (Tables 2 and 3). Regarding ultrasound clinic atten-
ance, FM was more  frequently associated with ultrasound
xamination (6.1% vs. 2.9% of visits; p = 0.047). Among RA
atients with FM,  biologics use was less frequent when ultra-
ound examination was performed: 9.1% vs. 66.7% of visits;
 = 0.002.
No statistically significant differences were found between
roups concerning 7-year biologic-free survival, and radio-
raphic progression-free survival in Cox regression adjusted
y age, sex and CCI (Fig. 2). The only factor significantly
nfluencing 7-year biologic-free survival was age, HR = 0.966
0.944–0.988). Seven-year radiographic progression-free sur-
ival was not influenced by any of the variables.
Scenario A (overtreatment) was present in 15.3% of all visits
nd scenario B (undertreatment) was identified in 5.5% of all
isits. Overall, RA patients with FM were more  frequently over-
nd undertreated (scenarios A + B) when compared with those
ithout FM (28.4 vs. 19.8%, p < 0.001; Table 3).
iscussiono our best knowledge, this is the first longitudinal study
edicated to quantify the impact of FM on DMARD escala-
ion decision in an RA cohort. Recently, Lage-Hansen et al.described an increase in biologic DMARD use among RA
patients with FM in a cross-sectional study.18 However, due
to its transverse design no causality could be established. In
our study, DMARD escalation was not affected by FM possibly
due to physicians awareness of its presence. In 2009, our group
demonstrated the impact of FM on DAS28 in patients attend-
ing the same clinic.6 Therefore, rheumatologists were aware
of this interference early on in the study. Also, compared to
other disease activity scores, DAS28 is particularly prone to FM
interference, due to the heavier weight of subjective compo-
nents (tender joints count and visual analogue scales) in its
formula.14,19 By knowing DAS28 characteristics beforehand,
rheumatologists were more  careful in escalating DMARD in
RA patients with FM, emphasizing objective measures, such
as swollen joints count, erythrocyte sedimentation rate and C-
reactive protein, for treatment decision.10,20 In addition, since
2010, ultrasound has been performed for synovitis quantifi-
cation in our centre. As previously demonstrated, synovitis
on Doppler may better represent RA activity level than clin-
ical indexes in patients with concomitant FM.21,22 Moreover,
FM-induced DAS28 and HAQ overestimations diminished dur-
ing the study, possibly minimizing overtreatment. However,
no definite conclusion can be drawn from this observation.
RA patients with FM showed a deeper decline in DAS28
and HAQ values during follow up than those without FM,
probably because of several factors, such as the growing
body of evidence on FM treatment, the availability of new
Government-funded drugs for FM in 2011, the greater use of
tricyclic antidepressants among FM patients and the growing
access to the multidisciplinary Pain Treatment clinic in our
institution. Unfortunately, we do not have the frequency of
Pain Treatment clinic attendance or non-pharmacological
treatment (exercise and psychotherapy) adherence among FM
patients to verify this hypothesis. In 2008, Sokka et al. reported
a remission rate of 19.6% in a real-life setting.23 In another
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Table 2 – Treatment-related characteristics of patients per group throughout the study.
RA with FM RA without FM p valuea
(n = 32) (n = 224)
Years of follow up; mean (±SD) 5.7 6.2 0.301
Amitriptyline dose (mg/day); median (IQR) and mean (±SD) 0.0 (0.0, 25.0) 0.0 (0.0, 0.0) <0.001
13.4 (±23.5) 4.6 (±14.2)
Methotrexate dose (mg/day); median (IQR) and mean (±SD) 15.0 (0.0, 20.0) 15.0 (7.5, 20.0) <0.001
12.7 (±9.2) 14.2 (±8.6)
Leflunomide dose (mg/day); median (IQR) and mean (±SD) 0.0 (0.0, 20.0) 0.0 (0.0, 20.0) <0.001
8.2 (±9.9) 5.2 (±8.7)
Prednisone dose (mg/day); median (IQR) 5.0 (0.0, 10.0) 2.5 (0.0, 8.8) <0.001
Number of visits in use of biologics per patient-year; median (IQR) 0.9 (0.3, 1.2) 1.0 (0.6, 1.4) 0.638
DMARD escalations per patient-year; median (IQR) 1.0  (0.7, 1.5) 1.0 (0.7, 1.5) 0.530
Radiographic progression (%) 46.9 39.7 0.442
RA, rheumatoid arthritis; FM, fibromyalgia; SD, standard deviation; IQR, interquartile range; analgesics, acetaminophen, dipyrone, tramadol,
codeine; DMARD, disease-modifying antirheumatic drug.
a Student’s, Mann–Whitney’s or Pearson’s chi-square test was used accord
with statistical significance.
Table 3 – Treatment characteristics of each group
measured in visits throughout the study.
RA with FM RA without FM p valuea
(n = 373
visits)
(n = 2613
visits)
Tricyclic antidepressants
(%)
31.4 13.2 <0.001
Methotrexate (%) 69.4 79.8 <0.001
Leflunomide (%) 41.3 26.2 <0.001
Prednisone (%) 65.4 52.9 <0.001
Continuous analgesics (%) 21.7 12.7 <0.001
Continuous NSAIDs (%) 26.5 22.0 0.076
Biologic DMARD (%) 10.5 12.4 0.292
Abatacept (%) 1.1 0.9 0.773
Adalimumab (%) 1.3 2.1 0.346
Certolizumab (%) 0.0 0.0 NS
Etanercept (%) 0.0 3.2  <0.001
Golimumab (%) 0.0  0.0 NS
Infliximab (%) 5.1 3.4 0.112
Rituximab (%) 2.9 1.9 0.186
Tocilizumab (%) 0.0 0.8 0.075
DMARD escalations (%) 46.9 47.2 0.960
DMARD escalations in the
first year of follow up
(%)
51.6 49.5 0.400
Scenario A (%) 20.4 14.6 0.004
Scenario B (%) 8.0 5.2 0.023
DMARD, disease-modifying antirheumatic drug; RA, rheumatoid
arthritis; FM, fibromyalgia; analgesics, acetaminophen, dipyrone,
tramadol, codeine; NSAID, nonsteroidal anti-inflammatory drug;
NS, not stated; scenario A, DAS28 moderate/high, DMARD, escalated
and radiographic progression absent; scenario B, DAS28 mod-
erate/high, DMARD, not escalated and radiographic progression
present.
a Student’s, Mann–Whitney’s or Pearson’s chi-square test was used
according to nature and distribution of data; alpha = 0.050. In bold,
p values with statistical significance.
T2T study in long-standing RA, DAS28 and HAQ diminished
after 3 years (p = 0.004 and p < 0.001, respectively) and the
final scores were comparable to ours: DAS28 = 3.3 ± 1.4 and
HAQ = 1.1 ± 0.4. In this same study, remission was achieved
by 35.3% of patients initially refractory to synthetic DMARD.24
Santos-Moreno et al. studied moderately to highly activeing to nature and distribution of data; alpha = 0.050. In bold, p values
RA patients treated to target for 6 months and found a
significant decrease both in DAS28 and HAQ (p < 0.001). Their
final values were: DAS28 = 2.5 (2.3, 3.2), HAQ = 0.1 (0.1, 0.3) and
remission rate = 51%.25 In our study, the longer observational
period, joint deformities and chronic proliferative synovitis
seen in long-standing disease, as well as lower educational
level may have contributed to the final DAS28 slightly above
the target.8,26 Despite the greater decrease of DAS28 over
time among FM patients, the final score was higher in this
group but not the radiographic progression rate, suggesting
that the interference of the painful condition in RA activity
scoring was attenuated but still present throughout the
study.
RA patients with FM used more  often tricyclic antidepres-
sants, leflunomide, prednisone and continuous analgesics,
but less often methotrexate than those without FM.  Tri-
cyclic antidepressant indication was not collected and other
conditions, such as diabetic neuropathy, could have influ-
enced this difference. The greater use of the preferably
second-line agent leflunomide (Table 3) may indicate an
interference of the painful condition in DMARD escala-
tion (methotrexate discontinuation). Also, prednisone dose
was greater among FM patients (Table 3), suggesting FM
could have pushed steroid therapy forward. In the study
by Anderson et al., chronic widespread pain patients were
treated with prednisone to a greater extent than those with
chronic regional pain syndrome but a similar rate of DMARD
treatment.9
Radiographic progression was the same between groups
and comparable to other T2T studies.27,28 Possibly, no joint
damage difference was observed in the presence of FM
because DMARD escalation was similar to those without FM.
In addition, FM interference on treatment decision could have
been attenuated by ultrasound examination. Speculatively,
DMARD escalation decision could have become less biased by
FM afterwards.21,29,30
Kaplan–Meier curves contemplate the time elapsed
to a certain event and no differences between groups
were observed regarding biologic-free, and radiographic
progression-free. In other words, FM does not seem to antic-
ipate biologic use or radiographic progression among RA
r e v b r a s r e u m a t o l . 2 0 1 7;5 7(5):403–411 409
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Fig. 2 – Kaplan–Meier curves of RA patients with and without FM.  (A) 7-year biologic-free survival; (B) 7-year radiographic
progression-free survival. RA, rheumatoid arthritis; FM,  fibromyalgia. RA patients with FM as a continuous line and RA
patients without FM as an interrupted line. Cox proportional hazards models adjusted by age, sex, Charlson comorbidity
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atients. These results have not been described in equivalent
tudies yet.
Our findings suggest that RA patients with FM could have
een more  frequently mistreated than RA patients without
M in two arbitrary scenarios. In theory, these scenarios
ntend to represent both over- and undertreatment frequen-
ies. Nonetheless, no definite conclusion can be drawn, since
adiographic progression was not quantified in a score and
hese scenarios require further validation as true outcome
easures. Moreover, ultrasound scoring could be used in
uture studies as a comparator in each scenario, since it has
een validated as an objective measure of synovitis and as a
adiographic progression predictor.21,29
Ultrasound-based synovitis assessment could have influ-
nced DMARD escalation decision, contributing to reduce the
upposed influence of FM on RA treatment.21 A longitudinal
tudy with RA patients with FM divided in two groups accord-
ng to ultrasound assessment could address this issue more
roperly. Another imperfection was the existence of various
AS28 examiners throughout the study, as it has been demon-
trated that clinical reliability of the score is highly dependent
n the examiner.31 Since DAS28 was usually performed by the
rainee and confirmed by the senior rheumatologist and our
esults are similar to those of other real-life studies, we believe
he examiners variation was not a major bias for the results.
onclusions
n the present RA cohort, FM did not significantly impact
verall DMARD escalation, and FM-induced DAS28 and HAQ
verestimations diminished towards the end of the study.
owever, RA patients with FM used more  leflunomide and
rednisone, and RA mistreatment seems to be more  frequent
n FM patients. Certainly, RA patients with FM will benefit
rom a personalized T2T strategy, including objective synovi-
is biomarkers, such as ultrasound, parallel to a permanenterval); alpha = 0.050.
FM treatment optimization. Personalized medicine in RA is a
proficuous research field and more  studies on the impact of
FM on RA treatment would probably help improve decision-
making process in benefit of patients and the society.
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